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Abstract— To improve cancer diagnosis and drug 
development, the classification of tumor types based on 
genomic information is important.  As DNA microarray 
studies produce a large amount of data, expression data 
are highly redundant and noisy, and most genes are 
believed to be uninformative with respect to the studied 
classes.  Only a fraction of genes may present distinct 
profiles for different classes of samples.  Classification 
tools to deal with these issues are thus important.  
These tools should learn to robustly identify a subset of 
informative genes embedded in a large dataset that is 
contaminated with high dimensional noises.  In this 
paper, an integrated approach of support vector 
machine (SVM) and particle swarm optimization (PSO) 
is proposed for this purpose.  The proposed approach 
can simultaneously optimize the selection of feature 
subset and the classifier through a common solution 
coding mechanism.  As an illustration, the proposed 
approach is applied to search the combinational gene 
signatures for predicting histologic response to 
chemotherapy of osteosarcoma patients. Cross-
validation results show that the proposed approach 
outperforms other existing methods in terms of 
classification accuracy.  Further validation using an 
independent dataset shows misclassification of only one 
out of fourteen patient samples, suggesting that the 
selected gene signatures can reflect the chemoresistance 
in osteosarcoma. 
 
I.  INTRODUCTION 
Cancer is one of the leading causes of death in 
developed countries [34].  Studies reveal that many cancer 
patients were diagnosed at a late stage, which were more 
difficult to treat.  Cancer develops mainly in epithelial cells 
(carcinomas), connecting/muscle tissue (sarcomas), and 
bone marrow cells (leukaemia and lymphomas).  
Successive mutations in the normal cells lead to DNA 
damages and impair the replication mechanism, ultimately 
causing significant gene features that contribute to a 
cancerous state. 
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A microarray chip can simultaneously interrogate 
thousands of genes, which provides an extremely powerful 
tool for genomic studies of cancer.  A few key genes 
(typically involving oncogenes and tumour suppressor 
genes), when mutated, will cause deregulation of the 
transcription and translation of other genes through 
complicated signalling pathways to initiate oncogenesis, 
and ultimately leading to derangement of the cellular 
phenotype and the clinical manifestation of cancer [31].  
Analyzing microarray data could help discover some 
significant cancer genes and their mutual interactions, 
which can be used to generate hypothesis for the 
identification and validation of genetic biomarkers for 
diagnostic and therapeutic purposes [8, 17, 19, 21].   
Significance based methods (e.g. T-test, confidence 
intervals, etc.) [10], which aim at finding statistically 
significant genes in differentiating various patient groups, 
have been extensively used.  However, the common 
characteristic of these methods is to evaluate each 
individual gene one by one, thus neglecting the intrinsic 
interactions among genes.  Multivariate methods, instead, 
are highly desirable to identify a group of genes that can 
cooperatively regulate tumor patterns.  One of the 
commonly used approaches is to iteratively combine 
different genes as predictors for tumor classification.  Gene 
predictors that account for specific clinical phenotypes 
should classify tumor samples into different groups in a 
robust manner.  In other words, the performance of 
classification of a predictor can implicate significances of 
genes.  Classification problems have been addressed by 
different machine learning tools like neural network 
[5,15,23], k-nearest neighborhood [25], decision tree, self-
organizing maps [21], graph theory [22], and support 
vector machine (SVM) [4,12,18,25,30,32,35], etc.  
However, the choice and implementation of these tools are 
rather an empirical and experimental work.  In fact, the 
data-driven machine learning techniques suffer from the 
“curse of dimensionality”, which is a typical problem when 
analyzing microarray data.  On the other hand, the recent 
method [30] often solves the problems of feature selection 
and classifier optimization separately in tandem.  Gene 
features are selected first according to prior knowledge or 
their statistical significances.  Then the classifier is 
optimized based on the selected feature set.  There is no 
guarantee that the selected gene features can achieve 
optimal classification. 
In this paper, an approach that integrates support vector 
machine [4, 35] with particle swarm optimization (PSO) 
[20] is used to build a more reliable classifier.  This 
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approach incorporates gene features and SVM parameters 
into one common solution code.  The problem is solved by 
simultaneously optimizing the selection of gene features 
and the parameters of the SVM classifier.  The optimal 
solution achieved by this procedure may reach the best 
gene features and the corresponding optimal classifier.  We 
shall focus on osteosarcoma, which is the most common 
malignant bone tumor in children and accounts for 60% of 
malignant bone tumors diagnosed in the first two decades 
of life [26].  The current standard care procedure is to give 
neo-adjuvant chemotherapy after initial diagnosis is made, 
followed by definitive surgery and postoperative 
chemotherapy.  After surgery, the tumor will be 
categorized to be a good responder (>90% necrosis) or a 
poor responders (<90% necrosis) according to its response 
to pre-operative chemotherapy, and based on which a 
proper postoperative chemotherapy can be determined.  
Unfortunately the overall survival rate of the poor 
responders did not significantly improve [14, 26].  It is 
possible that resistant tumor cells have additional time to 
either metastasize to the lungs or evolve further during the 
period when ineffective preoperative chemotherapy is 
given.  Therefore it is necessary to identify at the time of 
initial diagnosis the patients who are likely to have a poor 
response to standard preoperative therapy and therefore a 
poor outcome eventually.  The DNA microarray data were 
collected from the tumor samples of patients enrolled in a 
clinical trial at the Texas Children’s Hospital.  Expression 
profiling by DNA microarray was done on tumor tissues 
before and after chemotherapy treatments.  The classifier 
was initially developed with the integrated approach to 
distinguish good responders and poor responders based on 
the sampled data after chemotherapy.  The results were 
compared with the existing methods tested on the same 
dataset [27] to verify its performance and robustness.  The 
derived classifier was further validated through predicting 
the potential chemo-response of biopsy samples acquired 
before chemotherapy. 
 
II.  DATA DESCRIPTION 
We use a set of osteosarcoma microarray data [27], 
which were generated through institutional review board-
approved protocols at four centers (Texas Children’s 
Hospital/Baylor College of Medicine, Cook Children’s 
Medical Center, Pediatric Branch of the National Cancer 
Institute, and University of Oklahoma Health Science 
Center).  A total of 34 samples (14 initial biopsies and 20 
definitive surgery specimens) were included [27], which 
were obtained from 28 individual patients with 18 males 
and 10 females.  Six patients contributed two samples each, 
both initial biopsies and definitive surgery specimens, 
whereas the remaining 22 patients contributed one sample 
each, either an initial biopsy or a definitive surgery 
specimen.  The initial biopsy samples were obtained at the 
time of diagnosis before the initiation of preoperative 
chemotherapy.  The definitive surgery samples were 
collected after the completion of preoperative 
chemotherapy.  The drug responses are centrally reviewed 
by one pathologist after definitive surgery.  Good response 
is defined as more than 90 percent necrosis in tumor, and 
poor response with less than 90 percent necrosis. 
It is clinically useful to monitor drug response after 
chemotherapy so that further therapeutic measures could 
be adjusted to optimize the chance of survival of the poor 
responders as revealed at the time of definitive surgery.  
Another more significant approach is to predict the drug 
response before chemotherapy is initiated, which provides 
clinicians the option to customize therapy based on the 
predicted response. Therefore the gene arrays of the 20 
definitive surgery specimens can be used to train the 
classifier, and the gene arrays of the 14 initial biopsies can 
be used to verify the trained classifier. 
To process the gene data, the raw quantification outputs 
of all array experiments were pre-processed and filtered by 
removing spots with low signal intensity and low sample 
variance (P > 0.01), as well as those that were missing in 
the experiments.  A total of 1,934 genes remained after 
pre-processing and filtering. The intensities were then 
normalized by an intensity dependent local weighted 
regression method.  After normalization, the intensity 
ratios were log-transformed before further analysis. 
 
III. CLASSIFICATION AND FEATURE SELECTION WITH 
SUPPORT VECTOR MACHINE 
Let a gene microarray dataset D be denoted by 
( ){ }liii YX 1, = , where mi RX ∈ is the gene expression level of 
the i-th patient, { }1,1−∈iY  is the condition label for a 
binary classification problem, and m is the number of gene 
features.  The dataset after performing gene selection is 
defined as ( ) ( )( ){ }liii YXD 1, == with 'mR∈ , where the 
function ( )⋅  selects m' (<m) gene features among all the m 
gene features from the gene expression data set D.  With 
SVM, all training samples are mapped to the feature space 
by a non-linear function ( )( )iXφ .  A separating hyperplane 
in the feature space can be expressed 
as ( )( ) '
1
and0, m
l
i
iiii RwXyw ∈∑ ≥=
=
αφα .  The optimal 
separating hyperplane is defined as a linear classifier which 
can separate the two classes of training samples with the 
largest marginal width, and the optimal parameters 
[ ]iαα =  are obtained by maximizing the following 
function: 
 
( ) ( )( ) ( )( )[ ]∑ ∑ ⋅−=
= =
l
i
l
ji
jijijii XXyyW
1 1,2
1 φφαααα  (1) 
 
with liCi ,...,1,0 =≤≤ α in which C is the regularization 
parameter controlling the tradeoff between model 
complexity and empirical risk.  In the hyperplane 
expression, only those items with 0>iα  can remain.  The 
samples that lie along the margins of the decision boundary 
(by Kuhn-Tucker theorem) are called support vectors, 
which satisfy the equation: 
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( )( ) 0≥∑= iiii whereXyw αφα    (2) 
 
To avoid the computation of the inner product 
( )( ) ( )( )ji XX φφ ,  in the high dimensional space during 
the optimization of (1), the kernel function that can satisfy 
the Mercer’s condition is introduced: 
 
( ) ( )( ) ( )( ) ( )( )jiji XXXXK φφ ,, =    (3) 
 
Typical kernel functions like linear, sigmoid, radial 
basis function (RBF) can be used.  RBF is widely used as 
the kernel function in gait classification studies [12, 35].  
As there is no analytical study for choosing the optimal 
kernel function, it is usually chosen by trial and error, 
which depends on the problem nature.  As a result, the 
selected kernel to the problem may not be a good one.  An 
integrated kernel that combines different kernels is 
proposed in this paper.  The parameters in the integrated 
kernel could be found by some tuning algorithm.  
 
∑=
=
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1
3
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where K1, K2, K3 are the linear, sigmoid and radial basis 
functions respectively, and ω1 is the weight for each kernel.  
For a new test sample X, a decision function of an SVM 
classifier with a kernel K can then be defined based on the 
selected gene subset: 
( ) ( ) ( )( )
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛
∑ +=
VECTOR
SUPPORT
iii bXXKyDXf ,sgn,, α  (6) 
 
To develop a robust SVM model based on the training 
set in a practical way, the leave-one-out cross-validation 
(LOOCV) can be applied.  Under this approach, one 
sample is left out as a testing sample, and the remaining 
1−l samples are employed as training samples.  
Let ( ){ }l kiiiik YXD ≠== ,1, represent the training set, the overall 
accuracy is reflected by: 
 
( ) ( ) ⎟
⎠
⎞⎜
⎝
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1
,,
2
1,,   (7) 
 
where J(X, D, l) is the total error of the classifier.  Now the 
integrated gene feature selection and SVM classification 
problem are transformed to optimizing the above single 
objective function (7) by searching the feature selection l 
and the SVM parameters in f(·). 
 
IV.  PSO WITH WAVELET MUTATION (WPSO) 
Consider a swarm X(t) at the t-th iteration.  Each particle 
( ) ( )tXtp ∈x  contains κ elements ( ) ( )ttx ppj x∈  at the t-th 
iteration, where p = 1, 2,...  , γ  and j = 1, 2,… , κ ; γ  
denotes the number of particles in the swarm.  First, the 
particles of the swarm are initialized and then evaluated 
based on a defined fitness values.  The objective of PSO is 
to minimize the fitness value (cost value) of a particle 
through iterative steps.  The swarm evolves from iteration t 
to t +1 by repeating the procedures as shown in Fig. 1.  The 
velocity ( )tv pj  (corresponding to the flight speed in a 
search space) and the position ( )tx pj  of the j-th element of 
the p-th particle at the t-th generation can be calculated 
using the following formulas : 
 
( ) ( )( ) ( )( )
( )( )1()
1()1
2
1
−−⋅⋅+
−−⋅⋅+−⋅=
txgbestrand
txpbestrandtvwtv
p
jj
p
j
p
j
p
j
p
j
p
j
p
j
ϕ
ϕ
 (8) 
 
( ) ( ) ( )tvktxtx pjpjpj ⋅+−= 1     (9) 
 
where ppbest = [ ]ppp pbestpbestpbest κ,...21  and 
gbest = [ ]κgbestgbestgbest ,...21 .  The best previous 
position of the p-th particle is recorded and represented as 
ppbest ; the position of the best particle among all the 
particles is represented as gbest; w is an inertia weight 
factor; 1ϕ  and 2ϕ  are acceleration constants; ()
p
jrand  
returns a uniform random number in the range of [0,1]; k is 
a constriction factor derived from the stability analysis of 
(8) to ensure the system converges but not prematurely [6].  
PSO utilizes ppbest  and gbest to modify the current search 
point in order to prevent the particles from moving in the 
same direction, but to converge gradually toward ppbest  
and gbest.  A suitable selection of the inertia weight w 
provides a balance between the global and local 
explorations.  Generally, w can be dynamically set with the 
following equation [7]: 
 
t
T
wwww ×−−= minmaxmax     (10) 
 
where t is the current iteration number, T is the total 
number of iteration, maxw  and minw  are the upper and 
lower limits of the inertia weight, and are set to 1.2 and 0.1 
respectively in this paper.  In (8), the particle velocity is 
limited by a maximum value maxv .  The parameter maxv  
determines the resolution, or fitness, of regions between 
the present position and the target position to be searched.  
This limit enhances the local exploration of the problem 
space, and depicts the incremental changes of learning. 
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Fig.1.  Pseudo code for WPSO 
 
Before generating a new X(t), the wavelet mutation 
operation is performed.  The resulting WPSO has the 
following mutation operation: Every particle of the swarm 
will have a chance to mutate governed by a probability of 
mutation [ ]10∈mμ , which is defined by the user.  For 
each particle, a random number between 0 and 1 is 
generated such that if it is less than or equal to mμ , the 
mutation will take place on that element of the particle.  
For instance, if ( ) ( ) ( ) ( )[ ]txtxtxt pppp κ,,, 21 …=x  is the 
selected p-th particle and the particle element ( )tx pj  is 
randomly selected for mutation (the value of ( )tx pj  is 
inside the element’s boundaries [ ]jj parapara maxmin , ), the 
resulting particle is given 
by ( ) ( ) ( ) ( )[ ]txtxtxt pppp κ,,, 21 …=x , 
 
( ) ( ) ( )
( )
( ) ( )( )⎪⎩
⎪
⎨
⎧
≤−×+
>−×+
=
0 if  
0 if  
min
max
σσ
σσ
jp
j
p
j
p
j
jp
jp
j paratxtx
txparatx
tx  (11) 
 
where j ∈ 1, 2, …, κ .  Using the Morlet wavelet as the 
mother wavelet, we have 
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2
2
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The value of the dilation parameter a is set to vary with 
the value of Tt  in order to meet the fine-tuning purpose, 
where T is the total number of iteration and t is the current 
number of iteration.  In order to perform a local search 
when t is large, the value of a should increase as Tt  
increases so as to reduce the significance of the mutation.  
Hence, a monotonic increasing function governing a and 
Tt  is proposed as follows. 
 
( ) ( )g
T
tg
wm
ea
ln1ln +⎟
⎠
⎞
⎜
⎝
⎛ −×−
=
ζ
     (13) 
 
where wmζ  is the shape parameter of the monotonic 
increasing function, g is the upper limit of the parameter a. 
 
V.  FORMULATION OF WPSO OPTIMIZATION SYSTEM 
The number of features in microarrays is significantly 
larger than the number of samples.  In order to improve the 
performance of the classification, reducing the dimension 
of the data set is necessary, and the filter technique has 
been adopted for this purpose. 
As shown in Fig. 2, the two-sample t-test is performed 
to pre-screen the noisy genes, and the remaining unfiltered 
genes are the more significant genes.  The t-value of the 
gene feature can be determined by the following equation: 
1
1
1
1
11
−
−
−
+
−=
n
Var
n
Var
t μμ     (14) 
where 1n  and 1−n  are the numbers of patients with positive 
and negative conditions.  1μ  and 1Var  are the mean value 
and variance of gene feature in the positive group, and 1−μ  
and 1−Var  are the mean value and variance of gene feature 
in the negative group.  The gene features with low t-values 
are filtered out, and the ones with high t-values are passed 
to the WPSO optimization unit, which can search for the 
most significant gene features and the SVM parameters for 
classification.  Practically, the gene features that have t-
values higher than 2.5 are passed to the WPSO 
optimization unit and the rest of the gene features are not 
considered.  
In the WPSO selection, the algorithm provides a binary 
encoded particle where each bit represents a gene.  If a bit 
value is 1, that gene is kept in the subset; and the bit value 
of 0 indicates that the gene is not included in the subset.  
Therefore, the particle length is equal to the number of 
genes in the subset.  Based on the selected gene features 
from the binary coded representation, the SVM classifier is 
then trained in Step 2b with real coded parameters through 
leave-one-out-cross-validation (LOOCV), during which 
the cost function is used to evaluate the fitness of a 
solution 
 
,C),,D,error= J(Xfitness σ=    (15) 
 
begin 
         t→0                    // iteration number 
         Initialize X(t)     // X(t): Swarm for iteration t 
         Evaluate f(X(t)) // f(⋅): fitness function 
while (not termination condition) do 
           begin 
t→t+1 
// Process of SPSO // 
Update velocity v(t) and position of each 
particle x(t) based on (8) and (9) respectively 
if v(t)>vmax 
v(t)= vmax 
end 
if v(t)<−vmax 
v(t)= − vmax 
end 
Perform mutation operation with pm 
Reproduce a new X(t) 
Evaluate f(X(t)) 
            end 
end 
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The objective of the WPSO is to minimize the fitness 
function by searching the optimal gene feature.  It can be 
seen that the best fitness value is zero if there is no any 
error.  On realizing the WPSO, the following simulation 
conditions are used: 
• Shape parameter of the wavelet mutation ( wmζ ): 0.2 
• Probability of mutation ( mμ ): 0.2 
• Acceleration constant 1ϕ : 2.05 
• Acceleration constant 2ϕ : 2.05 
• Constriction factor k: 0.005 
• Parameter g: 1000 
• Swarm size: 20 
• Number of iteration: 1000 
• Initial population X(0): all the particles are initialized 
randomly 
• Initial global best gbest: it is generated uniformly at 
random  
• Initial previous best ppbest : it is generated uniformly 
at random. 
 
VI.  RESULT AND ANALYSIS 
The SVM classifier was first trained by the sample data 
training set to classify the tumour to be a good responder 
or a poor responder.  The best gene combination can be 
derived according to its cross-validation accuracy.  Then 
the gene subset and the trained SVM classifier will be 
verified by using the data test set.  The results show the 
relevance of using the selected gene combination as the 
signature of chemoresistance, and the ability of this gene 
signature to predict at the time of initial diagnosis the 
histologic response as determined at the time of definitive 
surgery. 
The result of the proposed algorithm was used to 
compare with the results of various supervised 
classification algorithms (compound covariate predictor 
CCP, linear discriminant analysis LDA, 1-nearest neighbor 
1-NN, 3-nearest neighbor 3-NN, nearest centroid NC and 
SVM) collected from [27].  For all algorithms, LOOCV 
was used to fairly evaluate the performance of each 
classifier, and all of them can only achieve 60-70% 
classification accuracies.  In the training, the proposed 
method can achieved 80% classification accuracy, as 
shown in Table 1. That means out of the 20 samples of 
training sets, there are 16 samples that can be classified 
successfully. Comparing with other methods, the proposed 
method is a more robust technique for gene signature 
selection and classification. 
The weights of kernels ω1, ω2 and ω3 were found to be 
0.533, 0.1663 and 0.3007 respectively. In this paper, there 
are 937 genes selected as the predictor genes; however, 
there is not enough information to explain the cooperative 
relationship among genes in the subsets. 
 
 
tumor ID of 
the training 
sets 
Histologic 
response  
concordance of classification with histologic response 
CCP LDA 1-NN 3-NN NC 
proposed 
method 
300 Good No No No No No No 
308 Good Yes Yes Yes Yes Yes Yes 
386 Good No No No No No No 
394 Good No No No No No No 
452 Good Yes Yes Yes Yes Yes Yes 
759 Good Yes Yes Yes Yes Yes Yes 
771 Good Yes Yes Yes Yes Yes Yes 
221 poor Yes Yes Yes Yes Yes Yes 
236 poor Yes Yes Yes Yes Yes Yes 
241 poor Yes Yes Yes Yes Yes Yes 
252 poor Yes Yes Yes Yes Yes Yes 
311 poor Yes Yes Yes Yes Yes Yes 
342 poor Yes Yes Yes Yes Yes Yes 
392 poor Yes Yes Yes Yes Yes Yes 
483 poor Yes Yes Yes Yes Yes Yes 
591 poor Yes Yes Yes Yes Yes Yes 
680 poor No No No No No Yes 
691 poor No No No No No Yes 
760 poor No Yes Yes Yes No Yes 
761 poor No No No No No No 
% correctly classified 65% 70% 70% 70% 65% 80% 
Table 1. LOOCV of 20 definitive surgery osteosarcoma samples 
 
The optimal SVM classifier with the selected gene 
subset was then respectively applied to predict the chemo-
response of the 14 initial biopsy samples for further 
validation purpose.  The test data are completely 
independent of the training data and process.  In the testing, 
the corresponding SVM classifier misclassified one sample 
among the 14 samples, with a correct classification rate of 
92.9%, as shown in Table 2.  The results in [27] also 
misclassified Tumor ID 410 of a clinically good responder 
as a poor responder. This finding is consistent with the 
study in [27], where it was pointed out that this patient 
initially presented with localized disease but eventually 
developed recurrence in the lungs 25 months after the 
completion of therapy, suggesting that there were resistant 
cells present in the initial biopsy, which might have 
metastasized to the lungs before definitive surgery and 
subsequently gave rise to the recurrent tumor. This result 
further indicates that the gene expression signature of the 
resistant cells in the definitive surgery samples was already 
present in the initial biopsy samples at the time of 
diagnosis. 
Tumor 
ID 
Histologic 
response 
Classified by 
proposed algorithm 
410 Good No 
197 Poor Yes 
207 Poor Yes 
278 Good Yes 
289 Poor Yes 
345 Good Yes 
204 Poor Yes 
274 Poor Yes 
299 Good  Yes 
464 Poor Yes 
479 Poor  Yes 
481 Poor Yes 
545 Good  Yes 
654 Good Yes 
Table 2.  Classification results of the proposed algorithm. 
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VII.  CONCLUSION 
In this paper, we have proposed an integrated approach 
of WPSO and support vector machine to select a compact 
gene subset and optimize parameters simultaneously.  
Prediction of chemo-response using an independent dataset 
of 14 initial biopsy samples achieved 92.9% of accuracy, 
reflecting that the proposed algorithm is promising in 
selecting gene signatures that the derived genes are 
consistently expressed in initial biopsy samples and thus 
have predicting value for drug response.  The results 
suggest that the proposed algorithm can be used to 
generate hypothesis for the identification and validation of 
genetic biomarkers for diagnostic and therapeutic purposes.  
In the future, we will further validate the proposed 
algorithm in solving other similar classification problems 
with large data sets of nasopharyngeal carcinoma and lung 
cancer. 
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 Fig. 2.  Illustration for the proposed algorithm.
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